Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era

Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab

(2023) Valentina Damato et al.   NEUROMUSCULAR DISORDERS

Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19

(2023) Chan Mi Lee et al.   Frontiers in Immunology

Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity

(2022) Momoko Morishita et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

The T cell immune response against SARS-CoV-2

(2022) Paul Moss   NATURE IMMUNOLOGY

Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values

(2022) Christina S. Thornton et al.   Antimicrobial Resistance and Infection Control

Vaccine-induced T cells against Sars-Cov-2 and its Omicron variant in B cell-depleted lymphoma patients after CART

(2022) Djordje Atanackovic et al.   BLOOD

Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection

(2022) Chang Kyung Kang et al.   BMC Medicine

Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy

(2022) Murat Bektaş et al.   CLINICAL IMMUNOLOGY

Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection

(2022) Pyoeng Gyun Choe et al.   JOURNAL OF INFECTIOUS DISEASES

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

(2022) Tommy Nyberg et al.   LANCET

Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity

(2022) Chang Kyung Kang et al.   Frontiers in Immunology

Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies

(2022) Roberto Alfonso-Dunn et al.   Frontiers in Immunology

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

(2022) Brian MacKenna et al.   Lancet Rheumatology

Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review

(2022) Chao Wang et al.   JOURNAL OF MEDICAL VIROLOGY

Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review

(2022) T. Jefferson et al.   JOURNAL OF HOSPITAL INFECTION

COVID-19 CG enables SARS-CoV-2 mutation and lineage tracking by locations and dates of interest

(2021) Albert Tian Chen et al.   eLife

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy

(2021) Rémy Duléry et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prolonged COVID-19 Disease in a Patient with Rheumatoid Arthritis on Rituximab Therapy

(2021) Rachel Aviv et al.   JOURNAL OF INFECTIOUS DISEASES

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

(2021) Sokratis A. Apostolidis et al.   NATURE MEDICINE

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

(2021) Matthias B Moor et al.   Lancet Rheumatology

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

(2021) Jérôme Avouac et al.   Lancet Rheumatology

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

(2021) Laith J. Abu-Raddad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study

(2021) Mario Habek et al.   JOURNAL OF NEUROIMMUNOLOGY

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

(2021) Anne Constanze Regierer et al.   RMD Open

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

(2021) L Boekel et al.   Lancet Rheumatology

Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity

(2020) Chang Kyung Kang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Cell-Mediated Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors

(2020) Chang Kyung Kang et al.   JOURNAL OF INFECTIOUS DISEASES

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis

(2020) Nitzan Nissimov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

(2020) Ana Zabalza et al.   EUROPEAN JOURNAL OF NEUROLOGY

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

(2019) Celine Kaegi et al.   Frontiers in Immunology

Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

(2018) Keith A Sacco et al.   Immunotherapy